Blog Articles
What is Veoza? – fezolinetant

What is Veoza? – fezolinetant

Navin Khosla NowPatientGreen tick
Medically reviewed by Navin Khosla, BPharm and written by Rajive Patel, BPharm - Updated on 28 Dec 2023
Share this post
Table of contents
OverviewUnderstanding Vasomotor Symptoms and their ImpactIntroducing Veoza: A First-in-Class Treatment OptionHow Veoza Works: Targeting the Root Cause of Hot FlashesClinical Trials and Efficacy of VeozaSafety Considerations and PrecautionsVeoza Availability and Future ProspectsConclusion: A New Era in Menopausal Symptom ManagementSources

Menopause is a natural phase in a woman’s life when her menstrual periods cease, typically occurring between the ages of 45 and 55. One of the most common and bothersome symptoms of menopause is vasomotor symptoms (VMS), which include hot flashes and night sweats. These symptoms can be disruptive, affecting a woman’s daily activities, sleep, and overall quality of life. For decades, there have been limited safe and effective treatment options for managing VMS. Hormone replacement therapy (HRT) has been the most effective treatment, but it may not be suitable for all women due to various contraindications. However, a breakthrough treatment called Veoza, also known as fezolinetant, has recently been approved by regulatory authorities in the United States and the United Kingdom.

Understanding Vasomotor Symptoms and their Impact

Vasomotor symptoms, commonly referred to as hot flashes or hot flushes, are characterized by sudden and intense feelings of heat, often accompanied by sweating and flushing of the face, neck, and chest. These common symptoms of menopause can last for several minutes and occur multiple times throughout the day and night. Hot flashes are experienced by approximately 70% of women going through menopause and can significantly impact daily life. They can disrupt sleep, cause discomfort, and affect mood and cognitive function.

Introducing Veoza: A First-in-Class Treatment Option

Veoza, also known by its generic name fezolinetant, is a groundbreaking new drug approved by the U.S. Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for the treatment of moderate to severe vasomotor symptoms associated with menopause. It is the first non-hormonal neurokinin 3 (NK3) receptor antagonist to receive regulatory approval for this indication.

The approval of Veoza marks a significant milestone in women’s health, offering a new non-hormonal treatment option for those who experience bothersome hot flashes and night sweats during the menopausal transition. Unlike hormone replacement therapy, which involves the use of estrogen and progesterone, Veoza acts directly on the brain’s temperature control centre and reduces the frequency and severity of hot flashes.

How Veoza Works: Targeting the Root Cause of Hot Flashes

Before menopause, there is a delicate balance between estrogens, hormones produced by the ovaries, and neurokinin B (NKB), a brain chemical. This balance regulates the body’s temperature control centre located in a specific area of the brain. However, as the body goes through menopause, estrogen levels decline, and this balance is disrupted. This hormonal imbalance can lead to the uncomfortable and disruptive symptoms of hot flashes for menopausal women.

Veoza works by blocking the activity of the NK3 receptor in the temperature control centre of the brain. By doing so, it helps restore the balance between estrogens and NKB, thereby reducing the frequency and intensity of hot flashes. This unique mechanism of action makes Veoza a promising and effective treatment for menopausal vasomotor symptoms.

Clinical Trials and Efficacy of Veoza

The approval of Veoza was supported by extensive clinical trials, including three phase 3 studies collectively enrolling over 3,000 participants across the United States, Canada, and Europe. The pivotal trials, known as SKYLIGHT 1™ and SKYLIGHT 2™, demonstrated the efficacy and safety of fezolinetant in reducing the frequency and severity of hot flashes in women with moderate to severe symptoms.

In these trials, women who received Veoza experienced a significant reduction in the frequency of hot flashes compared to those who received a placebo. After 12 weeks of treatment, Veoza reduced hot flash frequency by approximately 60% compared to a 45% reduction in the placebo group. Additionally, women reported improvements in the severity of hot flashes and the quality of their sleep.

The long-term safety profile of Veoza was further characterized in the SKYLIGHT 4™ study, a 52-week safety trial. The study demonstrated that Veoza was generally well-tolerated, with the most common side effects being abdominal pain, diarrhoea, difficulty sleeping, back pain, hot flashes, and elevated liver transaminases.

Safety Considerations and Precautions

While Veoza offers a promising treatment option for menopausal vasomotor symptoms, there are certain precautions and contraindications to be aware of. Before starting Veoza, it is essential to discuss your medical history, including any liver or kidney problems, with your healthcare provider. Veoza is not recommended for individuals with severe liver impairment, severe renal impairment, or end-stage renal disease. Regular liver function monitoring is advised during treatment.

In clinical trials, some women experienced elevations in liver transaminase levels, which returned to normal upon discontinuation or dose interruption. If you experience symptoms such as nausea, vomiting, or yellowing of the skin or eyes, it is important to seek medical attention promptly. Veoza should also be avoided in individuals taking certain medications known as CYP1A2 inhibitors.

Additionally, Veoza has not been studied extensively in women over the age of 65, so no specific dose recommendation can be made for this population. It is important to consult with your healthcare provider for personalized guidance and dosage adjustments if necessary.

Veoza Availability and Future Prospects

Veoza is a prescription-only medication that is available in the form of film-coated tablets. The recommended dose is 45 mg once daily, taken orally with or without food. The tablets should be swallowed whole and not crushed or chewed.

Currently, Veoza is available privately, and the manufacturer, Astellas Pharma, has initiated the process of seeking approval for NHS availability in the UK. The pricing of Veoza is yet to be determined by the Department of Health and Social Care. In the United States, the cost of Veoza is set at $550 for a 30-day supply. It is expected that Veoza will become more widely accessible to women seeking relief from menopausal vasomotor symptoms soon.

Conclusion: A New Era in Menopausal Symptom Management

The approval of Veoza marks a significant advancement in the treatment of menopausal vasomotor symptoms. This non-hormonal medication offers a novel mechanism of action, targeting the root cause of hot flashes and providing women with an effective and safe alternative to hormone replacement therapy. With its ability to reduce the frequency and severity of hot flashes, Veoza has the potential to improve the quality of life for countless women experiencing the challenges of menopause.

As further research and clinical experience with Veoza accumulates, it is anticipated that its availability and efficacy will continue to expand, offering hope and relief to women navigating the menopausal transition. If you are experiencing bothersome hot flashes and night sweats, it is recommended to consult with a healthcare professional to determine if Veoza is a suitable treatment option for you.


Medical Disclaimer

NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information in this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.

The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.

What is NowPatient

Telehealth and Online Pharmacy

NowPatient is a licensed online pharmacy and doctor service that is available around the world. Our service is FREE and packed with valuable features that can benefit your health such as medication reminders, educational blogs, medically approved symptoms checker, UK NHS online pharmacyprivate treatment plansRx Advantage cardhealth conditions information, affordable medications options, genetic testinghome test kitshealth riskspollen meterair quality monitor, and lots more!

See how we are different
A pink bottle of pills and a bottle of medicine.


To improve the lives of everyone by making high-quality care accessible and convenient

We are here to improve lives. Our service gives you access to smart features and resources that can help empower you to take control of your health and improve your health outcomes. All this, in one place, for FREE. We strive to bring a fresh perspective to managing health. NowPatient can be accessed by downloading the App or using your web browser.

Download our app today

A mobile phone with a health app and a pollen meter.

Can I trust NowPatient

Meet our medical review team

Trustworthy and reliable medical content authored and reviewed by our experienced team of medical professionals from the United Kingdom and the United States. Learn more about our team and our editorial process by clicking on the buttons below.


Medical Review Team Avatars

Your Questions Answered

For your peace of mind, we can answer your questions quickly

We have a comprehensive list of FAQ’s on each feature page. Alternatively, for broader questions around our service just click the button below.
Find your answers